Was it really a smart move for the FDA to approve a ‘smart pill’ for treating schizophrenia?

Ed Silverman
Researchers argue regulators may have handed drug makers a new avenue for evergreening, or patent extensions based on modest enhancements.

In late 2017, the Food and Drug Administration approved the first so-called smart pill, ushering in a new era of medical care. The inaugural effort involved embedding a sensor in Abilify, an old drug for treating schizophrenia and bipolar disorder, which can make it easier to track whether patients take their medicine, an especially thorny issue for people suffering from mental illness.

But in a new study, several researchers claim the regulatory endorsement was misguided.

Continue to STAT Plus to read the full story…